The Oncology Institute (NASDAQ: TOI) adds Mark D. Stolper as director and Audit Committee chair

Rhea-AI Filing Summary

The Oncology Institute, Inc. reported that its Board of Directors, by unanimous written consent, appointed Mark D. Stolper to fill a vacancy on the Board effective January 2, 2026. The Board’s Nominating and Corporate Governance Committee determined that he meets Nasdaq’s independence requirements and has the expertise to contribute effectively. He has been appointed to the Audit Committee, will serve as its Chairman, and has been designated the Audit Committee financial expert.

Mr. Stolper’s term runs until the next annual meeting of stockholders, when he is expected to be nominated as part of management’s slate. He will participate in the company’s non-employee director compensation program, receiving $75,000 per year, paid quarterly, plus restricted stock unit awards for his Board service and role as Audit Committee Chairman, to be granted at a later date. The company also issued a press release on January 5, 2026 announcing his appointment.

false 0001799191 0001799191 2026-01-02 2026-01-02 0001799191 TOI:CommonStockParValue0.0001Member 2026-01-02 2026-01-02 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2026-01-02 2026-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

Form 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  January 2, 2026

___________________________________

THE ONCOLOGY INSTITUTE, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware		001-39248		84-3562323
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA		90703
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:  (562) 735-3226

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		TOI		The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share		TOIIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of New Director

Through action taken by Unanimous Written Consent, effective January 2, 2026, the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”) filled a vacancy on the Board by appointing Mark D. Stolper to the Board. After conducting appropriate due diligence, the Nominating and Corporate Governance Committee of the Board determined that Mr. Stolper was a qualified candidate who meets the independence requirements under Nasdaq listing rules and has the expertise to contribute effectively to the Board. In connection with his appointment, the Board has appointed Mr. Stolper to the Audit Committee where he will serve as the Audit Committee Chairman and has been designated the Audit Committee financial expert. Mr. Stolper’s term as a director will expire at the Company’s next annual meeting of stockholders, at which time it is expected that he will be nominated as part of management’s slate of director nominees.

There are no arrangements or understandings between Mr. Stolper and any other person pursuant to which he was selected or appointed a director, nor are there any transactions between Mr. Stolper and the Company that would be reportable under Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Mr. Stolper will participate in the Company's non-employee director compensation program. A complete description of the Company's non-employee director compensation program is set forth in the Company's proxy statement for the 2025 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on March 27, 2025 (“2024 Director Compensation”). In line with this non-employee director compensation program, he will receive $75,000 per annum, paid quarterly, and will be granted restricted stock unit awards (“RSUs”) for service on the Board and as Audit Committee Chairman, which grant will be made at a later date.

Item 7.01 Regulation FD Disclosure.

On January 5, 2026, the Company issued a press release announcing the appointment of Mr. Stolper. The full text of the press release is attached as Exhibit 99.1 to this report and is hereby incorporated by reference herein.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the company or the operating partnership under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit No.		Description
99.1		Press Release issued by The Oncology Institute, Inc. on January 5, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 7, 2026	THE ONCOLOGY INSTITUTE, INC.
	By:	/s/ Mark Hueppelsheuser
		Mark Hueppelsheuser
		General Counsel

FAQ

What did The Oncology Institute (TOI) disclose in this 8-K filing?

The company disclosed that its Board of Directors appointed Mark D. Stolper as a director effective January 2, 2026, filling a vacancy on the Board and assigning him to key audit oversight roles.

What role will Mark D. Stolper have at The Oncology Institute (TOI)?

Mark D. Stolper has been appointed to the Board of Directors, will serve on the Audit Committee, act as its Chairman, and has been designated the Audit Committee financial expert.

Is Mark D. Stolper considered an independent director under Nasdaq rules for TOI?

Yes. The Nominating and Corporate Governance Committee determined that Mr. Stolper meets the independence requirements under Nasdaq listing rules and is a qualified candidate to serve on the Board.

How long will Mark D. Stolper serve on TOI’s Board under this appointment?

His term as a director will expire at the company’s next annual meeting of stockholders, when it is expected that he will be nominated as part of management’s slate of director nominees.

What compensation will TOI pay to Mark D. Stolper as a non-employee director?

Under the company’s non-employee director compensation program, Mr. Stolper will receive $75,000 per annum, paid quarterly, and will be granted restricted stock unit (RSU) awards for his Board service and role as Audit Committee Chairman.

Did TOI disclose any related-party transactions with Mark D. Stolper?

The company stated that there are no arrangements or understandings pursuant to which he was selected as a director and no transactions with him that would be reportable under Item 404(a) of Regulation S-K.

Did The Oncology Institute issue a press release about the new director appointment?

Yes. The company issued a press release on January 5, 2026 announcing Mr. Stolper’s appointment, which is included as Exhibit 99.1 and incorporated by reference in the filing under Item 7.01.